A high-throughput drug screening system for HIV-1 transcription inhibitors

Journal of Biomolecular Screening

Volumn 11, Issue 7, 2006, Pages 807-815

  Kempf, Mirjam Colette ^a   Jones, Jennifer ^b   Heil, Marintha L ^b   Kutsch, Olaf ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c Heerskink School of Medicine   (United States)

Author keywords

Fluorescent proteins; High throughput drug screening; HIV 1 infection; HIV 1 Tat

Indexed keywords

[7 CHLORO 5 (1H PYRROL 2 YL) 3H BENZO[E][1,4]DIAZEPIN 2 YL]METHYLAMINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HIV 1 TRANSCRIPTION INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DRUG SPECIFICITY; DRUG STABILITY; FALSE POSITIVE RESULT; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; VIRUS INFECTION; VIRUS INHIBITION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; CELL LINE, TRANSFORMED; DRUG EVALUATION, PRECLINICAL; GREEN FLUORESCENT PROTEINS; HIV LONG TERMINAL REPEAT; HIV-1; KINETICS; LEUKOCYTES, MONONUCLEAR; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33749845927     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057106290292     Document Type: Article

References (31)

1. Rice AP, Mathews MB: Transcriptional but not translational regulation of HIV-1 by the tat gene product. Nature 1988;332:551-553.
2. Nabel G, Baltimore D: An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711-713.
3. Laspia MF, Rice AP, Mathews MB: HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989;59:283-292.
4. Fujinaga K, Cujec TP, Peng J, Garriga J, Rice DH, Grana A, et al: The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol 1998;72:7154-7159.
5. Herrmann CH, Rice AP: Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 1995;69:1612-1620.
6. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998;92:451-462.
7. Peng J, Zhu Y, Milton JT, Rice DH: Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 1998;12:755-762.
8. Yang X, Gold MO, Tang DN, Lewis DE, Aguilar-Cordova E, Rice AP, et al: TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A 1997;94:12331-12336.
9. Edwards TE, Sigurdsson ST: Electron paramagnetic resonance dynamic signatures of TAR RNA-small molecule complexes provide insight into RNA structure and recognition. Biochemistry 2002;41:14843-14847.
10. Mestre B, Arzumanov A, Singh M, Boulme F, Litvak S, Gait MJ: Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim Biophys Acta 1999;1445:86-98.
11. Dassonneville L, Hamy F, Colson P, Houssier C, Bailly C: Binding of Hoechst 33258 to the TAR RNA of HIV-1: recognition of a pyrimidine bulge-dependent structure. Nucleic Acids Res 1997;25:4487-4492.
12. Bailly C, Colson P, Houssier C, Hamy F: The binding mode of drugs to the TAR RNA of HIV-1 studied by electric linear dichroism. Nucleic Acids Res 1996;24:1460-1464.
13. Hamy F, Brondani V, Florsheimer A, Stark W, Blommers MJ, Klimkait T: A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry 1998;37:5086-5095.
14. Faber C, Sticht H, Schweimer K, Rosch P: Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B. J Biol Chem 2000;275:20660-20666.
15. Nifosi R, Reyes CM, Kollman PA: Molecular dynamics studies of the HIV-1 TAR and its complex with argininamide. Nucleic Acids Res 2000;28:4944-4955.
16. Brodsky AS, Erlacher HA, Williamson JR: NMR evidence for a base triple in the HIV-2 TAR C-G.C+ mutant-argininamide complex. Nucleic Acids Res 1998;26:1991-1995.
17. Brodsky AS, Williamson JR: Solution structure of the HIV-2 TAR-argininamide complex. J Mol Biol 1997;267:624-639.
18. Aboul-ela F, Karn J, Varani G: The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. J Mol Biol 1995;253:313-332.
19. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, et al: Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 1998;53:1097-1103.
20. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, et al: Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother 1997;41:1250-1255.
21. Hsu MC, Dhingra U, Earley JV, Holly M, Keith D, Nalin CM, et al: Inhibition of type 1 human immunodeficiency virus replication by a tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proc Natl Acad Sci U S A 1993;90:6395-6399.
22. Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, et al: A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis 1995;172:1246-1252.
23. Ferguson NM, Fraser C, Anderson RM: Viral dynamics and anti-viral pharmacodynamics: rethinking in vitro measures of drug potency. Trends Pharmacol Sci 2001;22:97-100.
24. Kutsch O, Levy DN, Bates PJ, Decker J, Kosloff BR, Shaw GM, et al: Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Antimicrob Agents Chemother 2004;48:1652-1663.
25. Ochsenbauer-Jambor C, Jones J, Heil M, Zammit KP, Kutsch O: T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. Biotechniques 2006;40:91-100.
26. Kutsch O, Benveniste EN, Shaw GM, Levy DN: Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002;76:8776-8786.
27. Fletcher R. Unconstrained Optimization. Vol. 1. New York: Wiley, 1981.
28. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
29. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
30. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
31. Turpin JA, Buckheit RW Jr, Derse D, Hollingshead M, Williamson K, Palamone C, et al: Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob Agents Chemother 1998;42:487-494.